Early Psychosis Clinical Trial
Official title:
Mental Healthcare Decision-Making and Decision Support Among Emerging Adults Enrolled in Coordinated Specialty Care for Early Psychosis
NCT number | NCT04373590 |
Other study ID # | 24734 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | February 27, 2019 |
Est. completion date | August 30, 2020 |
Verified date | February 2021 |
Source | Temple University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate the impact of an antipsychotic medication decision aid and interpersonal and cognitive factors, such as attachment style and motivation, on emerging adults' ability to engage in shared decision making regarding their medications.
Status | Completed |
Enrollment | 18 |
Est. completion date | August 30, 2020 |
Est. primary completion date | August 12, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 25 Years |
Eligibility | Inclusion Criteria: - Aged 18 to 25 years - Experiencing early psychosis, defined as psychosis lasting 18 months or less between the time when threshold symptom criteria were reached (as determined by the admitting CSC program assessor) and the date of CSC program enrollment - Planning to attend a medication appointment with a participating CSC psychiatrist - Ability to speak and understand English - Ability to provide informed consent as assessed by research staff using procedures discussed by Carpenter et al. (2000) including a demonstrated understanding and recall of study procedures, rather than passive consent, and allowance of repetition of study procedures until there is understanding and recall. Exclusion Criteria: - Have a legal guardian - Have identified co-occurring dementia, delirium, or intellectual disability that will likely affect their ability to provide informed consent or participate in the data collection procedures. |
Country | Name | City | State |
---|---|---|---|
United States | Psychosis Education, Assessment, Care and Empowerment (PEACE) | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Temple University |
United States,
Zisman-Ilani Y, Shern D, Deegan P, Kreyenbuhl J, Dixon L, Drake R, Torrey W, Mishra M, Gorbenko K, Elwyn G. Continue, adjust, or stop antipsychotic medication: developing and user testing an encounter decision aid for people with first-episode and long-te — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in antipsychotics knowledge | Scale to assess change in knowledge about antipsychotic medications over time (9 items) | Baseline (Pre-appointment interview ) and post appointment interview ( same 1 day of the appointment ) | |
Primary | Decision-making self-efficacy | Decision Self-Efficacy (DSE) scale to assess decision self-efficacy (11 items) | Post appointment interview (1 day of the appointment ) | |
Primary | Decision-making attitudes | Decision Attitude Scale (DAS) to assess decision-making attitudes (10 items) | Post appointment interview (1 day of the appointment ) | |
Primary | Decisional Conflict | Decisional Conflict Scale (DCS) to assess level of decisional conflict (15 items) | Post appointment interview (1 day of the appointment ) | |
Primary | Shared decision making | collaboRATE scale to assess level of shared decision making after an appointment (3 items) | Post appointment interview (1 day of the appointment ) | |
Primary | Change in medication adherence | Brief Adherence Rating Scale (BARS) to assess change in medication adherence over time (8 items) | Baseline (Pre-appointment interview ) and post appointment interview ( same 1 day of the appointment ), 3 months follow-up , 6 months follow-up . | |
Primary | Change in service use | Service Use and Resource Form for Monthly Items (SURF-M) scale to assess change in service use over time (66 items) | Baseline (Pre-appointment interview ) and post appointment interview ( same 1 day of the appointment ), 3 months follow-up , 6 months follow-up . | |
Primary | Service engagement | Service Engagement Scale (SES) to assess level of service engagement (14 items) | Baseline (Pre-appointment interview ) | |
Secondary | Apathy | Marin Apathy Evaluation Scale to assess apathy (18 items) | Baseline (Pre-appointment interview ) | |
Secondary | Attachment style | Experiences in Close Relationships-Revised (ECR-R) Questionnaire to assess attachment style (36 items) | Baseline (Pre-appointment interview ) | |
Secondary | Working alliance | Working Alliance Inventory (WAI) to assess alliance (36) | Baseline (Pre-appointment interview ) | |
Secondary | Trust | Trust in the Medical Profession Scale to assess level of trust in the clinician (11 items) | Baseline (Pre-appointment interview ) | |
Secondary | Cognitive functioning | Brief Assessment of Cognition in Schizophrenia (BACS) - a battery to assess aspects of cognition such as verbal memory and attention. | Baseline (Pre-appointment interview ) | |
Secondary | Insight | Birchwood Insight Scale to assess insight to the illness (8 items) | Baseline (Pre-appointment interview ) | |
Secondary | Self-stigma | Internalized Stigma of Mental Illness (ISMI) Scale - Brief Version, to assess mental health self-stigma (10 items) | Baseline (Pre-appointment interview ) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06032182 -
PSYCHE Cognitive Remediation & Social Recovery Study
|
N/A | |
Active, not recruiting |
NCT06192602 -
Effects of an Acceptance-based Medication Adherence Therapy for Recent-onset Psychosis
|
N/A | |
Recruiting |
NCT04411225 -
Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis
|
Phase 3 | |
Completed |
NCT04592042 -
Intervention to Improve Coping With Negative Emotions in Patients With Psychosis (Feel-Good-Study)
|
Early Phase 1 | |
Active, not recruiting |
NCT04166019 -
Effect of a Peer-led Self-management Program for Recent-onset Psychosis
|
N/A | |
Recruiting |
NCT04317807 -
R33: Levetiracetam in Early Psychosis
|
Phase 2 |